The cost-effectiveness of iruplinalkib versus alectinib in anaplastic lymphoma kinase-positive crizotinib-resistant advanced non-small-cell lung cancer patients in China
Article in Frontiers in Public Health (April 2024)
The most recent citing publications are shown below. View all 1,538 publications that cite this research output on Dimensions.
Article in Frontiers in Public Health (April 2024)
Article in Cancers (April 2024)
Article in Expert Review of Pharmacoeconomics & Outcomes Research (April 2024)